Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 13/20 | 0.67 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.45 |
| ▸ | NMT1 | P30419 | 2/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5835178 | 1.00 | UTS2R (0.67) | UTS2RAVPR1ANMT1MCHR1ERBB2 | |
| SCHEMBL5835567 | 0.89 | UTS2R (0.66) | UTS2R | |
| SCHEMBL5835566 | 0.89 | UTS2R (0.66) | UTS2R | |
| SCHEMBL5835488 | 0.87 | UTS2R (0.64) | UTS2R | |
| SCHEMBL5835485 | 0.87 | UTS2R (0.64) | UTS2R | |
| SCHEMBL5835527 | 0.87 | UTS2R (0.81) | UTS2RMCHR1ERBB2EPHA2KDR | |
| SCHEMBL5835523 | 0.87 | UTS2R (0.81) | UTS2RMCHR1ERBB2EPHA2KDR | |
| SCHEMBL5836691 | 0.86 | UTS2R (0.69) | UTS2RAVPR1ANMT1MCHR1 | |
| SCHEMBL5836700 | 0.86 | UTS2R (0.69) | UTS2RAVPR1ANMT1MCHR1 | |
| SCHEMBL5835323 | 0.85 | UTS2R (0.67) | UTS2RERBB2EPHA2KDREPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026349-B2 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-11 | — | — | US | claimed |
| EP-1385507-A4 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2005-11-23 | — | — | EP | claimed |
| US-20040152906-A1 | Sulfonamides | SHELL OIL COMPANY | 2004-08-05 | — | — | US | claimed |
| EP-1385507-A1 | SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-02-04 | — | — | EP | claimed |
| WO-2002089792-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | claimed |
| US-7026349-B2 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-11 | — | — | US | disclosed |
| EP-1385507-A4 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2005-11-23 | — | — | EP | disclosed |
| US-20040152906-A1 | Sulfonamides | SHELL OIL COMPANY | 2004-08-05 | — | — | US | disclosed |
| EP-1385507-A1 | SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002089792-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152906-A1 | Sulfonamides | UTS2R, PRSS2, STS | UTS2R 1/4885AVPR1A 1017/4885NMT1 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.